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††Ohio State University, Columbus, Ohio.BACKGROUND The subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) provides an alternative to the transvenous implant-
able cardioverter-deﬁbrillator (TV-ICD). Patients undergoing TV-ICD
explantation may be eligible for reimplantation with an S-ICD; however,
information on safety outcomes in this complex population is limited.
OBJECTIVE This analysis was designed to provide outcome and
safety data from S-ICD patients who received their device after
TV-ICD explantation.
METHODS Patients in the S-ICD IDE Study and EFFORTLESS Registry
with a prior TV-ICD explantation, as well as those with no prior
implantable cardioverter-deﬁbrillator (ICD), were included.
Patients were divided into 3 groups: those implanted with the
S-ICD after TV-ICD extraction for system-related infection (n¼ 75);
those implanted after TV-ICD extraction for reasons other than
system-related infection (n ¼ 44); and patients with no prior ICD
(de novo implantations, n ¼ 747).
RESULTS Mean follow-up duration was 651 days, and all-cause
mortality was low (3.2%). Patients previously explanted for TV-ICD
infection were older (55.5  14.6, 47.8  14.3 and 49.9 
17.3 years in the infection, noninfection, and de novo cohorts,The S-ICD System IDE Clinical Investigation (S-ICD IDE study) and the
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secondary prevention (42.7%, 37.2% and 25.6%; Po 0.0001) and
had higher percentages of comorbidities, including atrial ﬁbrillation,
congestive heart failure, diabetes mellitus, and hypertension, in line
with the highest mortality rate (6.7%). Major infection after S-ICD
implantation was low in all groups, with no evidence that patients
implanted with the S-ICD after TV-ICD explantation for infection were
more likely to experience a subsequent reinfection.
CONCLUSION The S-ICD is a suitable alternative for TV-ICD
patients whose devices are explanted for any reason. Postimplan-
tation risk of infection remains low even in patients whose devices
were explanted for prior TV-ICD infection.
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extraction for reasons such as end of life,6 infection,7,8 and
device malfunction or manufacturer advisory.9,10 Data from
the National Cardiovascular Data Registry (NCDR) ICD
Registry show that between April 2010 and June 30, 2011, of
174,499 hospital visits, 47% were repeat procedures for
reasons such as device upgrade, battery end of life, and
systemic infection,11 and it is known that complication rates
are higher with reimplantations, particularly if a lead
implantation or revision is involved.11,12 In addition, mor-
bidity and mortality are particularly high in patients with an
infected transvenous ICD (TV-ICD) system, especially
when a systemic infection or endocarditis is present,13 and
the risk of reinfection after system reimplantation is also of
concern.14
The subcutaneous ICD (S-ICD) was developed to provide
an alternative to the TV-ICD, because it is implanted without
any transvenous or epicardial leads. Studies demonstrating
the safety and effectiveness of the S-ICD have been
published,15,16 and the S-ICD appears to be a good alter-
native for a variety of patients eligible for a TV-ICD
system.17 In this retrospective analysis, we evaluated the
outcomes of patients undergoing S-ICD implantation
after extraction of a TV-ICD system for any reason. Mortal-
ity rates and intraoperative and postoperative complication
rates were examined and compared with those of patients
receiving an S-ICD as their initial ICD implant (de novo
implants).Methods
Patient population
Patients included in the pivotal safety and efﬁcacy study (S-
ICD System IDE Clinical Investigation) and the EFFORT-
LESS S-ICD Registry (Evaluation of Factors Impacting
Clinical Outcome and Cost-Effectiveness of the S-ICD)
were assessed for this analysis. The design and methodology
for each study have been published in detail elsewhere.15,18
The main trial results of the IDE were published in 2013,15
whereas a preliminary report on overall performance of the
S-ICD system in EFFORTLESS was published in 2014.16
Recently, the initial safety and efﬁcacy results from the
pooled dataset with 2-year follow-up were also reported.19
Brieﬂy, the IDE study was a prospective, nonrandomized
study designed to evaluate the safety and efﬁcacy of the
S-ICD system for US Food and Drug Administration
approval. A total of 330 patients were enrolled, of whom
314 received an S-ICD implantation. Mean follow-up
duration was 661 days, with a range of 17 to 1012 days. In
contrast, the ongoing EFFORTLESS Registry has enrolled
1000 patients and is a standard-of-care post-market evalua-
tion documenting the long-term clinical outcome of S-ICD
patients followed up for 5 years in 9 countries. At the time of
the present analysis, data were available from the ﬁrst 581
patients who received S-ICDs. Thirteen patients were
common between the 2 studies. Sixteen patients available
at the time of analysis were not included because of lack ofinformation on prior TV-ICD implantation status, which left
an analysis cohort of 866 patients. The poolability of study
data, event deﬁnitions, and event adjudications have been
described previously.15,16,19 Ethical approval was obtained
at all centers for the purpose of each study, and all patients
provided informed consent according to national and institu-
tional regulations.
Three separate groups were analyzed, which consisted of
(1) repeat procedures in which the S-ICD implant was to
replace a previous TV-ICD extracted for infection; (2) repeat
procedures in which the S-ICD implant was to replace a
previous TV-ICD extracted for reasons other than infection;
and (3) S-ICD patients whose devices were implanted as an
initial procedure, or de novo implants. All groups were
evaluated for all-cause mortality; infection rates after S-ICD
implantation, and other procedural and device-related
complications.
Clinical complications
All clinical events collected in both studies were independ-
ently monitored. Events were documented and then sub-
classiﬁed into complications or observations. Complications
were those that required a prolonged hospitalization or a
need for reintervention. All deaths were automatically
classiﬁed as complications independent of underlying cause.
Complications were additionally classiﬁed as to whether
there was a relation to the S-ICD system or the implantation
procedure. An implantation-related complication was
deﬁned as any complication that was directly or indirectly
caused by the implantation procedure. A device-related
complication was deﬁned as any event related to the
implanted S-ICD system, including lead-, tunneling tool–,
and generator-related complications. In the event that a clear
relationship could not be documented but could not be ruled
out, a conservative classiﬁcation of the complication as being
related to the S-ICD system or procedure was adopted.
Statistical and data analysis
Baseline demographics and clinical variables, including
medical history, risk factors, comorbidities, and New York
Heart Association functional class for heart failure, are
presented as available. Continuous variables are summarized
as means with standard deviations or as medians and ranges
where appropriate. Continuous data were compared by the
Student t test. Categorical variables are summarized as
frequencies and percentages and were compared with χ2
test. Complication-free rates were analyzed with the Kaplan-
Meier methodology. All statistical analyses were performed
with SAS Enterprise Guide, version 5.1 (SAS 9.3).
Results
A total of 866 patients from 31 clinical centers were included
in the analysis. Follow-up data for complications and
mortality were available for all patients. For the ongoing
EFFORTLESS Registry, the data reﬂect information avail-
able as of November 18, 2013; for the IDE Study, the data
Table 1 Reasons for TV-ICD explantation
Primary indication for
TV-ICD explantation
S-ICD reimplantation after
TV-ICD extraction
Infection 75 (63.0)
End of battery life 5 (4.2)
Lead fracture/failure/advisory 30 (25.2)
Device malfunction 1 (0.8)
Thrombus on lead 8 (6.7)
Total 119 (100)
Values are n (%).
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patients, 747 had de novo implants (86.3%), whereas 75
(8.7%) had reimplantation procedures after extraction of a
TV-ICD for system-related infection and 44 (5.1%) after
extraction of a TV-ICD for reasons other than infection. The
indications for TV-ICD explantation are shown in Table 1. In
patients whose TV-ICD was explanted for reasons other than
infection, the majority of explantations (68.2%) were
because of transvenous lead failure or advisory alerts.
Whether infection was the reason for the TV-ICD explanta-
tion was captured for all patients. The nature of the infection
was not speciﬁcally collected, although there were sufﬁcient
data collected on the case report form to identify that at leastTable 2 Baseline demographics and clinical characteristics divided by
Demographic
Reimplantation: Prior
TV-ICD infection
Reimp
no in
Age (y)
Mean  SD 55.5  14.6 47.8
Range 19.0–86.0 18.
Sex
Male 56 (74.7) 28
Female 19 (25.3) 16
Height (cm) 173.7  9.8 175.2
Weight (kg) 85.8  21.4 79.1
BMI (kg/m2)
Mean  SD (median) 28.3  6.1 (26.8) 25.6
Range 16.4–51.7 17.
Indication
Primary prevention 43 (57.3) 27
Secondary prevention 32 (42.7) 16
Ejection fraction (%) 41.8  17.0 46.3
Medical history
NYHA class II to IV at enrollment 31 (41.3) 9
Atrial ﬁbrillation 19 (25.3) 5
COPD 6 (8.0) 2
Congestive heart failure 36 (48.0) 11
Diabetes mellitus 22 (29.3) 2
Hypertension 37 (49.3) 7
Myocardial infarction 39 (52.0) 10
Stroke 6 (8.0) 0
Valve disease 10 (13.3) 5
Ablation 5 (6.7) 7
CABG 14 (18.7) 4
Pacemaker 3 (4.0) 2
Percutaneous revascularization 24 (32.0) 10
Valve surgery 9 (12.0) 3
Values are n (%), mean  SD, or mean  SD (median).
BMI¼ body mass index; CABG¼ coronary artery bypass graft surgery; COPD¼
SD ¼ standard deviation.11 of 75 patients (14.7%) were suffering from a systemic
infection at the time of TV-ICD explantation. In 7 of these
patients (63.6%), endocarditis was speciﬁcally documented.
Mean follow-up duration for all S-ICD patients was 651
days, with a range of 2 to 1542 days (median 639 days).
There were no signiﬁcant differences in the mean follow-up
duration for each cohort. Demographic and clinical charac-
teristics of the 3 cohorts are shown in Table 2. The patients
whose devices were explanted for infection were signiﬁ-
cantly older than both the cohort of patients whose TV-ICD
was explanted for non–infection-related events and the de
novo implantation cohort, (55.5  14.6, 47.8  14.3, and
49.9  17.3 years, respectively; P ¼ .01); were more likely
to have the device implanted for secondary prevention
(42.7%, 37.2%, and 25.6%, respectively; P o .0001); and
had a higher incidence of comorbidities, including atrial
ﬁbrillation, congestive heart failure, diabetes mellitus, hyper-
tension, prior myocardial infarction, and stroke. In contrast,
those who received de novo implants had a signiﬁcantly
lower mean ejection fraction than either of the cohorts
undergoing TV-ICD extraction and S-ICD replacement
(38.7  17.5% and 46.3  19.3% for the non–infection-
related cohort and 41.8  17.0% for the infection-related
cohort; P ¼ .05).cohort
lantation: Prior TV-ICD,
fection
No previous TV-ICD
explantation (de novo) P value
.0146
 14.3 49.9  17.3
6–73.0 7.0–88.0
.3901
(63.6) 542 (72.6)
(36.4) 205 (27.4)
 9.2 174.5  10.4 .7257
 15.6 86.2  23.1 .1620
.0470
 4.1 (25.1) 28.3  6.7 (27.2)
4–35.7 15.2–69.0
o.0001
(62.8) 554 (74.4)
(37.2) 191 (25.6)
 19.3 38.7  17.5 .0314
(20.5) 284 (38.1) .0495
(11.4) 119 (15.9) .0720
(4.5) 47 (6.3) .7458
(25.0) 310 (42.7) .0399
(4.5) 130 (17.4) .0023
(15.9) 284 (38.1) .0014
(22.7) 252 (33.8) .0015
(0) 38 (5.1) .1591
(11.4) 98 (13.1) .9416
(15.9) 28 (3.8) .0006
(9.1) 83 (11.1) .1315
(4.5) 17 (2.3) .4559
(22.7) 160 (21.4) .1112
(6.8) 41 (5.5) .0800
chronic obstructive pulmonary disease; NYHA¼ New York Heart Association;
Table 3 Complication rates according to patient cohort
Reimplantation: Prior TV-ICD
infection (n ¼ 75)
Reimplantation: Prior TV-ICD,
no infection (n ¼ 44)
No prior TV-ICD explantation
(de novo) (n ¼ 747)
Complication description Events Patients Events Patients Events Patients P value
All complications 12 8 (10.7) 4 3 (6.8) 90 72 (9.6) 0.78
Device system infection 1 1 (1.3) 2 2 (4.5) 14 12 (1.6) 0.34
Erosion 1 1 (1.3) 1 1 (2.3) 10 9 (1.2) 0.83
Incision/superﬁcial infection 0 0 (0.0) 0 0 (0.0) 3 3 (0.4) 0.79
Values are number of events or n (%).
TV-ICD ¼ transvenous implantable cardioverter-deﬁbrillator.
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The total number of patients with system- or procedure-
related complications was not signiﬁcantly higher (P ¼ .78)
in the cohort whose TV-ICD explantation was for infection
(10.7%) than in either the cohort for whom TV-ICD
explantation was not related to infection (6.8%) or the de
novo S-ICD patient group (9.6%). Complication rates were
not driven by a high incidence of any speciﬁc event but
rather an accumulation of individual events (Table 3).
Because the risk of reinfection after system reimplantation
is of concern, the patient cohorts were also speciﬁcally
evaluated for reinfection rates after implantation with the
S-ICD. Figure 1 presents the Kaplan-Meier survival curves
for the incidence of infection up to 3 years after the S-ICD
implantation procedure for all 3 cohorts. During this period,
only 1 S-ICD patient (1.3%) from the cohort of patients
whose TV-ICDs were explanted because of infection devel-
oped a subsequent infection that required intervention,
speciﬁcally intravenous antibiotic drugs followed by explan-
tation. This rate was similar to the infection rate seen in the
de novo S-ICD implantation cohort, in which 12 patients
(1.6%) developed an infection that required intervention.Figure 1 Kaplan-Meier survival curves for freedom from infection. Survival
intervention after implantation of a subcutaneous implantable cardioverter-deﬁbril
(TV) device explantation because of infection; previous explantation for other reaIn the cohort of patients whose TV-ICDs were explanted for
reasons other than infection, the rate of infection after S-ICD
implantation was 4.5% (n ¼ 2 patients; P ¼ NS).
During follow-up, a total of 28 deaths were observed in
the entire study population (3.2%). None of the deaths were
related to either the S-ICD implantation procedure itself, S-
ICD infection, S-ICD therapy (appropriate or inappropriate),
or other S-ICD–related events but rather to worsening of
heart failure or other comorbidity (Table 4). Only 1 death
occurred within 30 days of implantation.19 The median time
between S-ICD implantation and death was 304 days.
Among the TV-ICD extraction cohorts, no patient deaths
were observed in the cohort reimplanted with an S-ICD after
extraction of a TV-ICD for reasons unrelated to infection,
whereas 5 deaths (6.7%) occurred in the cohort of 75 patients
whose TV-ICDs were extracted for infection, and 23 (3.1%)
occurred in the cohort of 747 patients without a prior
TV-ICD (P ¼ NS). In the patients with prior TV-ICD
extraction for infection, death was most often predominantly
caused by progression of heart failure and was never caused
by infection or reinfection (Table 4). The 3-year Kaplan-
Meier survival curves for each cohort are shown in Figure 2.curves documenting freedom from device-related infections that required
lator, according to status of prior device implantation: previous transvenous
sons; no previous explantation. Post-op ¼ postoperative.
Table 4 Causes of out-of-hospital mortality and corresponding time between S-ICD procedure and death according to cohort*
Death classiﬁcation No. of patients Days after S-ICD implantation
Reimplantation: Prior TV-ICD infection
Cardiac: Pump failure 3 124, 248, 820
Cardiac: Arrhythmic 1 617
Noncardiac (unspeciﬁed) 1 706
Total (% of population) 5 (6.7) Average ¼ 503  301 days
No prior TV-ICD explantation (de novo)
Cardiac: Pump failure 7 33, 246, 259, 331, 498, 530, 776
Cardiac: Arrhythmic 0
Noncardiac (unspeciﬁed) 6 81, 286, 582, 829, 1176, 1215
Pneumonia; respiratory failure 4 93, 151, 159, 493
Unknown 6 17, 226, 269, 270, 322, 753,
Total (% of population) 23 (3.1%) Average ¼ 417  338 days
S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator; TV-ICD ¼ transvenous implantable cardioverter-deﬁbrillator.
*There were no deaths among the reimplantation cohort with prior TV-ICD and no infection.
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Because complication rates, including mortality, have been
shown to be higher in patients undergoing repeat ICD
implantation procedures, particularly when a device is
explanted for infection, the current analysis was designed
to compare complication rates between patients who
received the S-ICD as a de novo implantation and those
whose devices were implanted after TV-ICD explanation for
any reason.
Over the past few years, expanding indications for ICD
implantation,2,3 including a younger primary prevention
population, coupled with more recent challenges related to
device and lead advisories and recalls20–22 have resulted in
increasing rates of reoperations and lead and full system
explantations, often with the need for reimplantation. Com-
plications associated with ICD explantations have been well
documented and, depending on the type of lead and its length
of time in the venous system, have been quite high.10–12Figure 2 Kaplan-Meier survival curves. Survival curves documenting mortality
(TV) device explantation because of infection; previous explantation for other reaThere are fewer prospective data, however, available that are
speciﬁcally related to the outcomes of patients who have
undergone reimplantation after extraction. The current study
provides insight into the long-term complication rates
associated with receiving an S-ICD as a replacement device
after TV-ICD extraction instead of a new transvenous lead
system, as well as providing reference data from a de novo
S-ICD cohort. The majority of patients included in the post–
TV-ICD extraction cohorts were explanted because of
infection (63%), of which 14.7% had a documented systemic
infection. Although this percentage is lower than previously
reported,23,24 this is likely a result of underreporting in both
the US IDE study and the EFFORTLESS Registry, because
there was no speciﬁc question in the case report form that
related to the type or severity of infection that resulted in
TV-ICD explantation. The second largest cohort of patients
included in the TV-ICD extraction population included those
whose system had been extracted because of lead failure,over 3 years according to status of prior device implant: previous transvenous
sons; no previous explantation. Post-op ¼ postoperative.
Heart Rhythm, Vol 13, No 1, January 2016162fracture, or as a result of a device advisory. Five patients
received the S-ICD after the extraction of a TV-ICD as a
result of battery end-of-life behavior, of whom 3 patients also
had documentation that at the time of extraction, there was
also a suspected or actual lead failure. Recent data from the
US NCDR ICD registry showed that more than 28% of ICD
reoperations that occurred for reasons of battery end-of-life
behavior also included a lead revision.11 In addition, Kramer
et al6 documented that 2.5% of patients (or 2759 patients)
having a TV-ICD replacement for battery end-of-life behav-
ior between January 2005 and March 2010 also had
concomitant device malfunction, recall, or infection.
Because the S-ICD system was not available during the
period of these 2 analyses, it remains to be determined
whether in such cases switching to the S-ICD will become a
common alternative to replace a TV-ICD system, particu-
larly in situations in which a lead also has to be revised.
The overall incidence of reported clinical complications
(approximately 11%) within the total patient population was
within the same range as other reports from the general
TV-ICD literature.11,25,26 Because each study used its own
limited deﬁnition of which clinical events would be reported,
it is difﬁcult to make a direct comparison of complication
rates within the S-ICD versus TV-ICD patient populations.
Both the S-ICD IDE study and EFFORTLESS Registry
collected data on all reported clinical events, which could
tend to result in overreporting. However, the key event rates
that could be compared between different studies (eg,
incidence of stroke, lead dislodgement, cardiac perforation)
appeared to be similar or even lower in the S-ICD patients.
The overall complication rate for TV-ICD patients whose
devices were explanted for infection was not signiﬁcantly
higher than for either of the other 2 S-ICD cohorts, and there
were no procedural or device-related events that were
documented to occur more frequently in any of the cohorts.
The incidence of S-ICD infection that results in explanta-
tion or revision in the overall cohort was 1.7%, which was
slightly higher than reported in the NCDR ICD Registry11 but
in line with rates from the Ontario ICD database12 and a recent
meta-analysis of 6433 patients included in 18 ICD trials.27
It should also be emphasized that none of the documented
S-ICD infections were systemic. Infection in the IDE Study15
and the Dutch S-ICD cohort report28 followed a temporal
pattern, with a peak observed early in the trial related to
inexperience with the new implantation technique. In the IDE
Study, once the optimal technique had been agreed on
between centers, there were no subsequent infections that
required explantation in the latter two-thirds of the study.15
The lack of an elevated infection rate in the cohort of
patients implanted with an S-ICD after TV-ICD explantation
for infection is notable. Maytin et al,29 whose data set
included outcomes of 520 transvenous lead extraction
procedures for an infectious indication, documented that
48% of patients who required a repeat extraction within the
course of the study (21.4  22.6 months) required this
procedure for another infectious cause. Although these
patients must have, by deﬁnition, received a replacementTV-ICD system, no details were given concerning the exact
time between the initial extraction and the subsequent
replacement procedure. In a smaller study by Deharo
et al,23 the time window from infected TV-ICD extraction
to reimplantation ranged from 10 to 1192 days, yet they
found no evidence that time to reimplantation was a predictor
of reinfection or subsequent mortality. Therefore, the obser-
vation that patients in whom an S-ICD is implanted after a
TV-ICD extraction because of infection are at no higher risk
of developing either a subsequent reinfection or requiring a
subsequent lead or system extraction is one of the most
important ﬁndings of the present study and suggests the
S-ICDmay be ideal as a reimplantation device in endocarditis-
related ICD patients without a pacing indication.
During follow-up, there were no procedural or S-ICD
device-related deaths, and the overall mortality rate of 3.2%
was lower than reported in other prospective clinical
evaluations of ICD patient outcomes.30 This may reﬂect
the fact that in general, patients included in the S-ICD trials
were younger and had a higher ejection fraction on average
than traditional TV-ICD clinical trial populations. Annual
mortality rates are reported to be higher among patients who
have undergone a transvenous device explantation than
among TV-ICD patients who have not. Importantly, the rate
is still higher in patients treated for infection. Maytin et al29
reported an 8.4% annual mortality rate in their population of
transvenous lead extraction patients, which increased to 25%
in the subgroup with systemic infection. Although it was not
speciﬁcally reported in their paper, it can be assumed that the
majority if not all of these patients would have been
reimplanted with a transvenous device. In the single-center
experience from Deharo et al,23 there was an 11.2%mortality
rate reported for patients who had undergone transvenous
system extraction for infection and subsequent reimplanta-
tion. In contrast, although S-ICD patients whose TV-ICD
was explanted for infection still had the highest mortality of
any of the S-ICD cohorts, the 6.7% rate was substantially
lower than the transvenous system cohorts described above.
The higher mortality rate for the S-ICD patients who
underwent TV-ICD explantation for infection does not
appear to be correlated with the presence of a prior infection,
as has been documented in TV-ICD studies,13 but appears to
reﬂect the morbidity demographics of this subgroup, which
had a higher percentage of secondary prevention indications
and incidence of signiﬁcant comorbidities than the other
cohorts presented here. Clearly, for all ICD patients,
reducing the potential for an initial infection and in particular
a systemic infection is likely to improve long-term outcomes.
For this reason, future data may demonstrate that the S-ICD
provides additional advantages over TV-ICDs as a de novo
implantation, because the risk of systemic infection should
be substantially lower.Study limitations
The current study is retrospective, with the intrinsic short-
comings of such a study, and the follow-up periods differed
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ciﬁc information on the history of the TV-ICD systems that
were replaced by an S-ICD, including number of prior leads
or generators and the nature of primary infections, is limited.
Time to S-ICD implantation after TV-ICD extraction was
also not prospectively gathered; however, time to implanta-
tion was also not identiﬁed in the largest comparative
transvenous extraction study,29 and in smaller comparative
studies has not shown to be a predictor of outcomes.13,23 The
patients included inherently had a higher likelihood of
survival, because they had survived their TV-ICD explanta-
tion and had been reimplanted with the S-ICD; therefore,
there was no true control group with which to speciﬁcally
compare outcomes. The sample size of the 2 TV-ICD
extraction cohorts is relatively small and may not allow
any deﬁnitive conclusions.
Conclusions
Patients reimplanted with an S-ICD after explantation of a
TV-ICD experienced low rates of major complications and
mortality compared with published data for transvenous
devices, which suggests that the S-ICD is a suitable alter-
native for TV-ICD replacement. In particular, the current
data provide evidence that patients implanted with an S-ICD
after explantation of a TV-ICD for infection do not experi-
ence elevated rates of reinfection.
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Because of expanding indications for implantable cardioverter-deﬁbrillators (ICDs) over the past 2 decades, the number of
patients in whom an ICD has been implanted has increased substantially. As implantation numbers increase, so inherently
does the incidence of both device and lead extraction procedures, particularly in light of a recent series of device
malfunctions and advisories. Coupled with a primary prevention population that is typically younger than the historic
secondary prevention patient, it is clinically essential that the risks associated with reimplantation are fully understood,
particularly if the patient’s device is being explanted for reasons of infection, which is often associated with a higher risk of
morbidity and mortality. The entirely subcutaneous ICD (S-ICD) was developed speciﬁcally to provide an alternative to the
transvenous ICD (TV-ICD), and although data are now available that in general support that the S-ICD is both safe and
effective, its performance in the more complex patient populations, such as those being reimplanted after explantation of a
TV-ICD system (whether for infection-related reasons or not), has not been established. The analysis presented here
addresses those concerns by demonstrating that overall morbidity and mortality rates associated with implantation of an
S-ICD after explantation of a TV-ICD are low, and in addition, that there is no increased risk of reinfection should a patient
have been explanted initially for transvenous device- or system-related infection. Practically, these data support that the
S-ICD may be ideal as a reimplantation device, particularly in endocarditis-related ICD patients without the need for
pacing.
